MabGenesis

Yokohama, Japan

MabGenesis is a biopharmaceutical startup company that offers therapeutic monoclonal antibody drugs for both humans and companion animals.

$3.0M raised

Dec 2024

Venture - Series Unknown

Top Investors

SMBC Venture CapitalBeyond Next VenturesMiyazaki Taiyo CapitalAxil CapitalANNIVERSAIRE

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has MabGenesis raised?

MabGenesis has raised $3.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in December 2024.

Who are MabGenesis's investors?

MabGenesis's investors include SMBC Venture Capital, Beyond Next Ventures, Miyazaki Taiyo Capital, Axil Capital, ANNIVERSAIRE.

Where is MabGenesis headquartered?

MabGenesis is headquartered in Yokohama, Japan.

What does MabGenesis do?

MabGenesis is a biopharmaceutical startup company that offers therapeutic monoclonal antibody drugs for both humans and companion animals.

What stage is MabGenesis at?

MabGenesis is at the Venture - Series Unknown stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated December 24, 2024.

MLA

"MabGenesis — Funding & Investors." VCBacked, December 24, 2024, https://www.vcbacked.co/company/mabgenesis. Accessed June 4, 2026.

APA

VCBacked. (2024). MabGenesis — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/mabgenesis

Wikipedia (cite web)

{{cite web |title=MabGenesis — Funding & Investors |url=https://www.vcbacked.co/company/mabgenesis |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated December 24, 2024.